Advertisement

David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement

Jul

01

Today In Oncology

Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

ASCO Remembers Karnofsky Award Recipient Maura Gillison Pioneer in HPV-Associated Cancers

Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs

Long-Term Outcomes With SABR in Primary Kidney Cancer

Advertisement

© 2026 HSP News Service, L.L.C.